|
2004
and 2003
Conference Reports, Treatment Guidelines and
Toxicities Management Guides Formatted for Print
|
|
HIV
and Hepatitis.com has
produced special reports on the Conference Meetings that are posted
on the web site in PDF
format.
z If you would like to have a hard
copy of the report mailed to you,
please e-mail
us your
name and mailing address.
|
 Critical
Issues In The Treatment and Management of CHRONIC HEPATITIS C
Introduction
Douglas
Dieterich, MD
HCV
Viral Kinetics and the Impact of Treatment With Peginterferon and
Ribavirin
Peter
Ferenci, MD
Weight-Based
vs Fixed Dosing of the Peginterferons
Thomas
Shaw-Stiffel, MD
Management
of the Toxicities and Side Effects of Peginterferon and Ribavirin
David Bernstein,
MD, FACP, FACG
HCV
Diagnostics
Jean-Michel
Pawlotsky, MD, PhD
Treatment
of HCV Infection in HIV-HCV Co-Infected Patients
Brian A. Boyle,
MD
|
Guide
to Management of
Protease
Inhibitor Drug
(PI) Toxicities and Side Effects
Fortovase
Invirase
Crixivan
Viracept
Norvir
Agenerase
Kaletra
Reyataz
Guide
to Management of
Non-Nucleoside
Reverse Transcriptase Inhibitor (NNRTI) Toxicities and Side Effects
Viramune
Sustiva
Rescriptor
Guide
to Management of
Nucleoside
/ Nucleotide
Analogue (NA) Drug Toxicities &
Side Effects
Retrovir
Zerit
Epivi
Videx
Viread
Ziagen
Hivid
|
Selected
Highlights from the
Digestive
Disease Week 2003 (DDW 2003) and from the
38th
Annual Meeting of the European Association of the Study of the Liver
(38TH EASL)
| Table
of Contents |
| Epidemiology
and Transmission of HCV |
| Evaluation
of HCV and Predictors of Treatment Success |
| Treatment
of HCV:Treatment-naïve |
| Treatment
of HCV: Relapse and Nonresponders |
| Treatment
of HCV: Management of Adverse Events |
| Treatment
of HCV: Special Populations |
| Treatment
of Chronic Hepatitis B |
|
Selected
Highlights from the
10th
Conference on Retroviruses and Opportunistic Infections
|
Summary
of Antiretroviral Therapy Clinical Trials
|
| The
2NN Study: Nevirapine- versus Efavirenz-based HAART Regimens |
| Clinical
Trials in Treatment Naïve and Experienced Patients |
| Treatment
Interruption Strategies and Immunology |
| Resistance
Testing |
| Adverse
Events Related to Antiretroviral Therapy |
| Metabolic
Disturbances and Lipodystrophy |
| Notable
Drug-Drug Interactions |
| New
Antiretrovirals in Development |
| Hepatitis
Co-infection and Liver Disease |
|
IAS
- USA Guidelines
Management
of Metabolic Complications Associated with Anti-HIV Therapy: Recommendations
of an International AIDS Society-USA Panel
|
Table
of Contents
|
| Insulin
Resistance and Abnormal Glucose Homeostasis |
| Lipid
and Lipoprotein Metabolism Abnormalities |
| Body
Fat Distribution Abnormalities |
| Lactic
Acidemia |
| Bone
Disease |
|
National
Institutes of Health Consensus Development Conference Statement -
Management of Hepatitis C: 2002
|
Table
of Contents
|
| What
is the natural history of hepatitis C? |
| What
is the most appropriate approach to diagnose and monitor patients? |
| What
is the most effective therapy for hepatitis C? |
| Which
patients with hepatitis C should be treated? |
| What
recommendations can be made to patients to prevent transmission
of hepatitis C? |
| What
are the most important areas for future research? |
|
